Nordovo Biosciences

Nordovo Biosciences is a clinical-stage biotechnology company dedicated to discovering and developing innovative biologics for the treatment of autoimmune and inflammatory diseases. The company leverages its proprietary antibody discovery platform to create highly potent and differentiated therapeutic candidates. Its lead program, NRD101, is a dual inhibitor targeting IL-17A and IL-17F, currently being evaluated in clinical trials for moderate-to-severe plaque psoriasis. Nordovo aims to address significant unmet medical needs by providing more effective and safer treatment options for patients worldwide. The company is headquartered in Suzhou, China, and is led by a team of industry veterans with extensive experience in global drug development.